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Background: Isolated hypogonadotropic hypogonadism (IHH) is a rare, clinically
heterogeneous condition, caused by the deficient secretion or action of gonadotropin
releasing hormone (GnRH). It can manifest with absent or incomplete sexual maturation,
or as infertility at adult-age; in a half of cases, IHH is associated with hypo/anosmia
(Kallmann syndrome). Although a growing number of genes are being related to this
disease, genetic mutations are currently found only in 40% of IHH patients.
Case description: Severe congenital hyposmia was diagnosed in a 25-year-old
Caucasian man referred to the Ear-Nose-Throat department of our clinic. The patient
had no cryptorchidism or micropenis and experienced a physiological puberty; past
medical history and physical examination were unremarkable. Olfactory structures
appeared hypoplasic, while hypothalamus, pituitary gland, and stalk were normal on
MRI (neuroradiological imaging); testosterone levels, as well as pulsatile gonadotropin
secretion and other pituitary hormones were unaffected at the time of first referral. At
the age of 48, the patient returned to our clinic for sexual complaints, and the finding
of low testosterone levels (6.8 and 5.8 nmol/L on two consecutive assessments) with
inappropriately normal gonadotropin levels led to the diagnosis of hypogonadotropic
hypogonadism. GnRH test was consistent with hypothalamic origin of the defect. Next
generation sequencing was then performed revealing a rare heterozygous allelic variant
in SPRY4 gene (c.158G>A, p.R53Q). The biological and clinical effects of this gene
variant had never been reported before. A diagnosis of Kallmann syndrome was finally
established, and the patient was started on testosterone replacement therapy.
Conclusion: This case describes the clinical phenotype associated with a rare SPRY4
gene allelic variant, consisting in congenital severe smell defect and adult-onset IHH; in
patients with apparently isolated congenital anosmia genetic analysis can be valuable
to guide follow up, since IHH can manifest later in adulthood. Characterization of other
modifying genes and acquired environmental factors is needed for a better understanding
of the physiopathology and clinical manifestations of this disease.
Keywords: Kallmann syndrome, anosmia, isolated hypogonadotropic hypogonadism, central hypogonadism,
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BACKGROUND
Isolated hypogonadotropic hypogonadism (IHH) is a rare
condition, with an incidence of 1:250,000 in females and 1:30,000
in males (1). It is caused by the deficient secretion or action
of gonadotropin releasing hormone (GnRH), and generally
manifests as incapacity to start or complete sexual maturation
at pubertal age, and infertility (2, 3). However, the syndrome is
clinically heterogeneous as micropenis and cryptorchidism can
be seen as early signs of severe GnRH deficiency occurring in
utero in a male infant (4); on the other hand, some patients
manifest hypogonadism only in adult life, after completion of
pubertal development (adult-onset IHH) (2, 3, 5–7).
IHH results from a failure in GnRH neurons’ development or
migration, or from a defective GnRH secretion or action. During
embryogenesis, indeed, immature GnRH neurons originate in
the olfactory epithelium, and then migrate in close association
with growing axons of olfactory nerves to finally reach the
forebrain (8, 9). This shared route explains the association
of IHH with defective olfaction in Kallmann syndrome (KS),
which is found in about 50% of IHH cases (2); furthermore,
other manifestations can be present in these patients, including
synkinesis, dental agenesis, digital bony abnormalities, cleft
palate, hearing loss, and unilateral renal agenesis (2, 5, 10).
Despite most cases of IHH are sporadic, families with congenital
IHH have been reported with X-linked, autosomal dominant and
autosomal recessive inheritance (11), and several genes have been
identified so far (10). Among these, some aremainly related to the
disruption of GnRH neurons’ development and migration (e.g.,
ANOS1, FGF8, FGF17, FGFR1, IL17RD, DUSP6, SPRY4, GLCE,
FLT3, PROK2, PROKR2, NSMF, WDR11, HS6ST1, SEMA3A,
SEMA3E, CHD7, TUBB3, SOX10), while others are implied in the
neuroendocrinological regulation of GnRH secretion (GNRH,
GNRHR, KISS1R, KISS1, TAC3, TACR3, LEP, LEPR) (12, 13).
Genetics of KS and normosmic IHH are largely overlapping,
but appear to explain only 40% of IHH patients, with other
cases remaining genetically uncharacterized (14); a possibly more
complex background is being disclosed in recent years, and
oligogenicity and gene-environment interactions are emerging in
the physiopathology of this disease (6, 15).
Here we describe the case of a male patient with congenital
anosmia and adult-onset IHH, in whom a rare allelic variant in
SPRY4 gene was found. The biological and clinical significance of
this mutation had never been reported before.
CASE DESCRIPTION
In 1994, a 25-year-old Caucasian man presented to the Ear-Nose-
Throat Department of our clinic for hyposmia and hypogeusia,
which the patient stated to be present since infancy; a Standard
Sniff Test was carried out, which was consistent with a severe
smell defect (Figure 1). Considering the possible association with
hypothalamus-pituitary-testis axis defects, the patient was then
referred to the Endocrinology department. The patient had no
cryptorchidism or micropenis at birth and had gone through
physiological puberty, with complete development of primary
and secondary sexual characteristics (Tanner stage 5); physical
examination was unremarkable: he was 186 cm tall and weighed
75 kg (body mass index, BMI: 21.7 kg/m2), with normal arm span
to height ratio and absence of gynecomastia; bitesticular volume
was 35mL, and he did not complain of any sexual symptom.
Past medical history was significant only for surgical detorsion of
the left testicle at the age of 13. No family history of infertility,
hyposmia, or pituitary diseases was reported, and his parents
were not consanguineous.
Early-morning total testosterone (TT) was 20.3 nmol/L
(5.8 ng/mL; normal values, n.v., 12.0–29.1 nmol/L); basal
Luteinizing Hormone (LH) and Follicle Stimulating Hormone
(FSH) levels were 1.22 IU/L (n.v. 1.7–8.6) and 1.63 IU/L
(n.v. 1.5–12.4), respectively, and they showed normal pulsatility
on frequent serum sampling and normal response to GnRH
test (Figures 2A,B); the remaining basal pituitary function was
unaffected, as well (Table 1). Skull magnetic resonance imaging
with contrast enhancement revealed absence of olfactory bulbs
and tracts and hypoplasia of olfactory sulci, while hypothalamus,
pituitary gland, and stalk were normal.
The patient was then lost to follow up until 2017 when, at
the age of 48, loss of libido, reduction in spontaneous erections,
and erectile dysfunction appeared. Bitesticular volume was 30mL
at this time, and a consistent weight gain occurred (BMI 25.9
kg/m2). Hormonal assessment showed definitely low testosterone
confirmed on a second sampling (TT 6.8 and 5.8 nmol/L on
two consecutive assessments, n.v. 12.0–29.1 nmol/L; calculated
free testosterone 61 pg/mL, n.v. > 65 pg/mL). Gonadotropin
levels were inappropriately-low (LH 2.1 IU/L, n.v. 1.7–8.6, and
FSH 4.2 IU/L, n.v. 1.5–12.4), but with preserved response to
GnRH stimulus (Figure 2B); LH secretion still occurred in
a pulsatile fashion as assessed on frequent serum sampling;
nevertheless, as far as one single LH peak was evaluated, LH
release profile appeared slightly flatter compared to the 1994
assessment (Figure 2A). The findings were thus consistent with
central hypogonadism (17) resulting from a hypothalamic defect.
Ferritin levels were within the normal range. Other pituitary
hormones were normal (Table 1), as well as number, motility, and
morphology of spermatozoa in semen analysis.
Bone mineral density was preserved at lumbar spine (T-score
−0.04, z-score−0.1), femoral neck (T-score+0.9, z-score+1.6),
and total hip (T-score+1.0, z-score+1.3).
Genetic analysis on 28 loci was obtained by next generation
sequencing (NGS). A single heterozygous missense allelic variant
in the exon 3 of SPRY4 gene (c.158G>A) was identified. This is
a rare gene variant (minor allele frequency < 0.01) leading to an
amino acid substitution at position 53 (p.R53Q), whose biological
and clinical effects had not been known so far. No other variants
in the 27 remaining loci were identified by NGS.
Following this result, a diagnosis of KS was finally established.
Other anomalies that have been found to occur in KS, namely
cleft lip and palate, synkinesis, sensorineural deafness, cerebellar
ataxia, renal agenesis, digital bony abnormalities, or dental
agenesis, were not present in the patient and his family.
The patient was not planning fertility and was started on
replacement therapy with transdermal testosterone, which was
effective in normalizing circulating testosterone levels and in
improving sexual symptoms.
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FIGURE 1 | Results of the sniff test performed at patient’s first referral. The first column indicates the 10 odorants employed; the second and the third columns
indicate the minimum amount of each substance that the patient was able to detect on the right or left nostril, respectively (first threshold); in normal individuals, the
first threshold is generally <3mL. The patient was also asked to identify the substances, and the patient’s answers are reported in the last column. The results are
consistent with a severe smell defect. N/D, not detected.
FIGURE 2 | (A) Spontaneous LH pulsatility assessed by frequent serum sampling. The graph depicts LH pulsatility assessed at the patient’s first referral in 1994 (solid
line) and upon hypogonadism symptoms’ manifestation in 2017 (dashed line) (LH reference values 1.7–8.6 IU/L); gonadotropin’s levels were measured at 20-min
intervals for 3 consecutive hours; secretion still occurred in a pulsatile fashion at both time points; nevertheless, as far as one single LH peak was evaluated, the LH
release profile appeared slightly flatter in 2017 compared to the 1994 assessment. (B) LH response to GnRH stimulation test. GnRH stimulation test was performed in
1994 (solid line) and then repeated in 2017 (dashed line). Blood was drawn before, and then 20, 30, and 60min after intravenous GnRH administration; a ≥400%
increase from baseline was considered normal (16). LH curves were similar at the two time points and both responses resulted normal, as levels increased by 26 folds
in 1994 and by 8 folds in 2017.
LABORATORY INVESTIGATIONS AND
DIAGNOSTIC TESTS
Olfactory evaluation was performed by Standard Sniff-Test; this
measure involves the unirhinal presentation of 10 odorants
(including pure olfactory, olfactory-gustatory, and olfactory-
trigeminal odorants) to each nostril for a total of 20 exposures.
Pyridine and water were, respectively, used as positive and
negative control. The test is based on the presentation to
the patient of progressively increasing volumes (from 1 up to
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TABLE 1 | Basal pituitary hormones’ assessment in 1994 and in 2017.
Reference values 1994 2017
TSH (mIU/L) 0.28–4.30 0.9 1.37
fT4 (ng/L) 8.0–17.0 16.5 11.2
Prolactin (mcg/L) 1.7–16.0 5.5 4.3
Cortisol (mcg/dL) 4.8–19.5 14.1 14.6
ACTH (ng/L) 0.0–46.0 N/A 24.2
IGF-1 (mcg/L) 50–200 N/A 148
Total testosterone (nmol/L) 12.0–29.1 20.3 6.8 and 5.8
LH (IU/L) 1.7–8.6 1.22 2.1
FSH (IU/L) 1.5–12.4 1.63 4.2
TSH, thyroid stimulating hormone; fT4, free thyroxine; ACTH, adrenocorticotropic
hormone; IGF-1, insulin-like growth factor 1 or somatomedin C; LH, luteinizing hormone;
FSH, follicle stimulating hormone; N/A, not assessed.
12mL) of air saturated with the specific olfactory substance,
which must be first detected (first threshold; normal <3mL)
and therefore recognized (second threshold); the different
thresholds are recorded, along with any wrong substance
identification (Figure 1).
Frequent serum sampling for LH and FSH pulsatility was
carried out by measurement of LH and FSH levels at 20-min
intervals for 3 consecutive hours.
For GnRH stimulation test, intravenous GnRH 100 mcg was
administered at 2-h intervals for three times when GnRH test
was performed for the first time in 1994; blood samples for LH
and FSH assessment were drawn before, and then 20, 30, 60,
90, and 120min after GnRH injection. In 2017, a single bolus
of GnRH was administered and blood samples for LH and FSH
were collected at 0, 20, 30, and 60min. A ≥400% increase from
baseline was considered normal (16).
Basal circulating levels of cortisol, ACTH, prolactin, IGF-
1, TSH, and fT4 were obtained for the study of the other
hypothalamus-pituitary axes.
Several candidate genes for IHH were analyzed by Next
Generation Sequencing. We extracted the genomic DNA of
the patient from peripheral blood lymphocytes using Gene
Catcher gDNA 96 × 10mL Automated Blood kit (Invitrogen,
Life Technologies
TM
, City, Country). The IHH gene panel was
designed using Illumina Design Studio (San Diego, CA, USA)
and included the following IHH candidate genes:ANOS1(KAL1),
FGFR1, PROKR2, PROK2, GNRHR, GNRH1, GNRH2, KISS1,
KISS1R, TAC3, TACR3, HS6ST1, FGF8, CHD7, DUSP6, FEZF1,
FGF17, FLTR3, IL17, SEMA3A, SEMA3E, SEMA7A, SOX2,
SOX10, SPRY4, WDR11, HESX1, NSMF (NELF). The 28
IHH genes consistently represented in all sequence capture
panels were assessed for the purposes of this study. Libraries
were prepared using Illumina Nextera Rapid Capture Custom
Enrichment kits according to the manufacturer’s protocols. All
regions not correctly sequenced were recovered with NexteraVR
DNA Library Preparation kit (Illumina, San Diego, CA, USA).
We included as “rare variants” (Manolio, T.A, Nature 2009)
all known pathogenic, or rare non-synonymous or splicing-
site variants (Minor Allele Frequency, MAF ≤ 0.01) and
novel non-synonymous or splicing-site variants. The frequency
and the functional annotation of the identified variants were
checked in public and licensed databases (Ensembl, UCSC
Genome browser, 1000 Genome project, ExAC Browser, NCBI,
HGMD professional), considering the ethnic group (Europeans).
As previously reported (18), we excluded common non-
synonymous variants with Minor Allele Frequency (MAF)
>0.01, synonymous, intronic, and 5
′
or 3
′
UTR variants.
Each variant found was confirmed by Sanger direct sequencing
using BigDyeVR Terminator v.3.1 Cycle Sequencing Kit (Life
Technologies, Carlsbad, CA, USA) on a 3100DNAAnalyzer from
Applied Biosystems (Foster City, CA, USA).
DISCUSSION
IHH is a rare and clinically heterogeneous condition; a number
of genetic alterations and non-genetic environmental triggers are
being unraveled in recent years (5). In the present case report we
had the unique opportunity to follow the natural clinical history
of a subject that was originally affected with isolated congenital
anosmia which evolved in a more complex phenotype in the
adulthood. Genetic phenotyping demonstrated the presence of a
rare allelic variant in SPRY4 gene, whose biological and clinical
significance has not been investigated so far1.
Indeed, the patient reported severe congenital hyposmia
and adult-onset IHH, which became evident many years
after completion of physiological puberty and was preceded
by significant weight gain; olfactory structures were
absent/hypoplasic on neuroradiological imaging. The hormonal
assessment was indicative of a hypothalamic defect in GnRH
secretion, while the remaining hypothalamus-pituitary axes were
unaffected. This case appears to fit well with the adult-onset KS
Italian cohort recently reported by Bonomi et al. (5) and showing
a high prevalence of overweight, and a hormonal profile similar
to the present case. Consistently, in the adult-onset form, weight
gain may affect GnRH activity and LH/FSH pulsatile secretion,
and may act as an acquired factor contributing to the onset of
IHH in genetically predisposed patients (6, 19).
SPRY4 (Sprouty RTK Signaling Antagonist 4) gene is located
on chromosome 5 and encodes a member of the human/mouse
SPRY family (SPRY1-SPRY4) (20). Particularly, SPRY4 belongs
to the so-called FGF8 synexpression group, a cluster of genes
which not only share an expression pattern similar to that of
FGF8 during embryonic development, but also act bymodulating
FGF8-FGFR1 intracellular signaling (21). The SPRY4 protein is
an inhibitor of the RAS-MAPK pathway, since it impairs the
formation of active GTP-RAS (20); it has been found to be
expressed in the olfactory placode in mouse embryos, and in the
hypothalamus of adult mice (22). SPRY4 knockout phenotype
includes craniofacial defects and abnormal limb development
(23). Miraoui et al. have identified SPRY4 allelic variants in 14
IHH patients, with both monogenic (n = 11) and oligogenic (n
= 3) patterns of inheritance (24); in all patients hypogonadism
had manifested before completion of physiological puberty; both
nIHH and KS were observed. With regard to Miraoui’s series,
1https://www.ncbi.nlm.nih.gov/snp/rs759316507#clinical_significance
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the mutation found in our patient manifests with a different
phenotype, considering the late onset of hypogonadotropic
hypogonadism and the congenital severe smell defect. On the
other hand, as recently reported in another study evaluating
both classic forms of IHH and adult onset forms (6), it seems
that, to some extent, the same genes are implied also in mild
diseases. In fact, SPRY4 was reported to be one of the loci
enriched in rare variants among patients harboring mild and
adult onset IHH, compared with both controls and classic
forms of hypogonadotropic hypogonadism. The case we are
reporting perfectly fits those epidemiological data: even if the
damaging potential of this new variant has to be clarified with
functional analyses and co-segregation studies, the congenital
severe anosmia and the olfactory structures’ alterations increase
the chances of causality, as these are known targets of this gene.
Moreover, we can hypothesize that the SPRY4 allelic variant,
found in our patient, might be sufficient to determine an early
impairment of the olfactory migration, while causing a fragility
of the GnRH neuron functionality that become evident only
later in the adult life. This may result from the degree of
disruption of the SPRY4 protein function itself; alternatively,
other unknown modifying genes, as well as in utero or acquired
environmental factors may have impacted the IHH phenotype.
Four patients with SPRY4 allelic variant have been previously
reported to manifest other non-reproductive features, namely
hearing loss and abnormal dentition (24); these can be present
in patients carrying FGF8-FGFR1 pathway defects (12), but were
not observed in the presented case.
In conclusion, we have reported for the first time the temporal
effect of a rare SPRY4 gene allelic variant found to be associated
with congenital severe smell defect and adult-onset IHH, in
the absence of other non-reproductive features; in patients with
congenital anosmia genetic analysis can be valuable to guide
follow up, since hypogonadotropic hypogonadism can manifest
later in life. Characterization of other modifying genes and
environmental factors influencing IHH phenotype is needed
for a better understanding of the physiopathology and clinical
manifestations of this disease.
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